MarginsXMarginsX
Home › Markets › Health Care › PAHC

Phibro Animal Health Corporation (PAHC)

PAHC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$35.02
-2.64% on the day
Market cap
$1.4B
Small cap
Revenue · 2026
$1.5B
+17.1% on 2025
Net income · 2026
$99.7M
6.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1069899/000110465926101493/0001104659-26-101493-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerPAHC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001069899
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2026

LineValue
Revenue$1.5B
Net income$99.7M
Operating income$194.4M
Net margin6.6%
Operating margin12.8%
Revenue growth+17.1%
Cash$61.4M
Total assets$1.5B
P/E (computed)14.3×
P/S (computed)0.9×

Warning signs

Cash runway
Cash-flow positive
$75.5M cash at September 30, 2026
Share count, 1 year
+0.2%
2025-10-31 to 2026-10-30
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$29.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$75.5M cash; operating cash flow $21.4M a quarter.Report 2026-09-30
Shares outstanding40,601,603 (2026-10-30); 40,533,608 a year earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey, United StatesPCAOB Form AP 2026-09-23
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $318K, sold $30.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
$386.8M$29.5M$26.1M$75.5M$610.9M$1.5B10-Q 2026-11-04
Q4 2026
2026-06-30
$396.7M$21.7M$24.1M$61.4M$616.8M$1.5B10-K 2026-08-26
Q3 2026
2026-03-31
$383.5M$24.0M$16.2M$54.9M$620.5M$1.5B10-Q 2026-05-06
Q2 2026
2025-12-31
$373.9M$27.5M$19.4M$55.5M$624.2M$1.5B10-Q 2026-02-04
Q1 2026
2025-09-30
$363.9M$26.5M$9.3M$72.8M$628.0M$1.4B10-Q 2026-11-04
Q4 2025
2025-06-30
$378.7M$17.2M$21.3M$68.0M$631.7M$1.3B10-K 2026-08-26
Q3 2025
2025-03-31
$347.8M$20.9M$43.2M$60.4M$635.4M$1.2B10-Q 2026-05-06
Q2 2025
2024-12-31
$309.3M$3.2M$3.1M$67.1M$639.1M$1.1B10-Q 2026-02-04

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FINAL PROSPECTUS
424B42014-04-14
Latest annual report10-K2026-08-26
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-09-18

Source: SEC EDGAR submissions feed, 774 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+9.1%
1 month-2.3%
3 months+5.6%
Year to date-3.7%
1 year-19.5%
From 52-week high-39.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NBTXNanobiotix S.A.$28.54-6.90%$1.5B
DMRADamora Therapeutics Inc.$22.50+4.14%$1.4B
LBRXLB Pharmaceuticals Inc$42.99-0.05%$1.4B
PCRXPacira BioSciences Inc.$36.48+0.05%$1.5B
URGNUroGen Pharma Ltd.$28.10+7.33%$1.4B
RAPPRapport Therapeutics Inc.$24.82-5.09%$1.5B
TYRATyra Biosciences Inc.$19.74-1.42%$1.4B
ANABAnaptysBio Inc.$45.73-1.12%$1.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier